Brought to you by 
AAA/EVAR device firm TriVascular Technologies' IPO nets $83.4mm
09 Sep 2020
Executive Summary
Only five months after returning to venture investors for a $40mm Series E round, TriVascular Technologies Inc. (minimally invasive devices for abdominal aortic aneurysms (AAAs)) netted $83.4mm in its initial public offering of 7.5mm shares (including the overallotment) at $12, below its planned $13-15 price range. Certain existing backers indicated an interest in buying $38mm of the IPO shares.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Sealants
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AAA/EVAR device firm TriVascular Technologies' IPO nets $83.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice